The FDA has granted orphan drug designation to Birchbiomed’s FS2 as a treatment for idiopathic pulmonary fibrosis, or IPF.

Researching IPF after her late husband's diagnosis meant learning many new acronyms and abbreviations, says guest writer.

Inhaled lipid nanoparticles loaded with two medicines reduced IPF lung stiffness and fibrosis in mice, outperforming an ...

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American ...

Bionews, Inc., the parent company of this site, has partnered with the following nonprofit advocacy organizations to help further the mission of ensuring that patients and caregivers are able to get ...

Columnist Samuel Kirton shares his emergency "go bag" checklist of things he brought when he received a bilateral lung transplant.

As an organ recipient, columnist Sam Kirton honors donors and their families each year by decorating holiday trees in the ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...